Cyclooxygenase-2 (Cox-2), the gastrin-release peptide (GRP) and its cognate receptor (GRP-R) are overexpressed in a significant percentage of colorectal carcinomas and are associated with cell growth, invasiveness and tumor progression. However, a molecular link between all of them in adenocarcinomas has not been established. Here, we show that bombesin (BBS), a GRP homolog, stimulates the expression of Cox-2 mRNA and protein in human colon adenocarcinoma Caco-2 cells, resulting in enhanced release of prostaglandin E 2 . These effects were markedly inhibited by the specific BBS antagonist RC-3940-II. BBS promotes the activation of the nuclear factor of activated T cells (NFAT) through a Ca 2 þ /calcineurin (Cn)-linked pathway. Upon BBS stimulation, the NFATc1 isoform translocates into the nucleus with a concomitant increase in NFATc1 binding to two specific recognition sites in the promoter region of the Cox-2 gene. Furthermore, inhibition of Cn activity by the immunosuppressive drug cyclosporin A impaired NFAT activation and diminished Cox-2 expression in BBSstimulated cells. Interestingly, BBS pretreatment strongly enhances the invasive capacity of carcinoma cells, effect which was inhibited by a Cox-2-specific inhibitor. These findings provide the first evidence for the involvement of the Ca 2 þ /Cn/NFAT pathway in BBS-mediated induction of genes involved in colon carcinoma invasiveness such as Cox-2. Oncogene (2007) 26, 958-969.
Introduction
Cyclooxygenases (Cox-1 and Cox-2) are considered to play an important role in human colon cancer, one of the major causes of mortality in developed countries (Kawai et al., 2002) . These enzymes catalyse the conversion of arachidonic acid to prostaglandins (PGs) and other eicosanoids. Cox-1 isoform is constitutively expressed in many human tissues. In contrast, Cox-2 is present at very low levels under basal conditions, but is rapidly induced in response to a panel of inflammatory, mitogenic and pro-oncogenic stimuli in a wide variety of cell types, including cancer cells (reviewed by Smith et al., 2000) . Considerable interest is currently focused on Cox-2 as a potential therapeutic target for the prevention and treatment of cancer (Kawai et al., 2002; Iniguez et al., 2003) . Numerous studies indicate that Cox-2 is overexpressed in 85-90% of cancerous tissues from human colon and inhibition of Cox-2 by nonsteroidal anti-inflammatory drugs decreases the risk of colorectal cancer (revised by Gupta and Dubois, 2001; Chan, 2002) . Experiments with Apc gene-deficient mice (Min mice) and Apc
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/Cox-2 double-knockout mice revealed that either pharmacologic inhibition or genetic ablation of Cox-2 resulted in reduced intestinal tumorigenesis (Oshima et al., 1996; Williams et al., 1996) . Enhanced synthesis of Cox-2-derived PGs may favor tumor growth by stimulating cell proliferation, promoting angiogenesis, inducing local immunosuppression, increasing invasiveness and inhibiting apoptosis (Kawai et al., 2002; Iniguez et al., 2003) . Nevertheless, Cox-2-specific inhibitors may significantly increase cardiovascular risk (Bresalier et al., 2005) and some clinical trials indicate that the Cox-2 inhibitor Rofecoxib has little effect on proliferation or apoptosis of colorectal cancer liver metastases (Fenwick et al., 2003) .
The mechanisms leading to enhanced Cox-2 expression in intestinal epithelial cells have not been fully elucidated. Both transcriptional and post-transcriptional mechanisms regulate Cox-2 expression in colon carcinoma (Shao et al., 2000; Cheng and Harris, 2002; Inoue et al., 2002; Ramsay et al., 2003; Dixon, 2004) . Moreover, depending on the stimuli, multiple signaling pathways including mitogen-activated protein kinases extracellular signalregulated kinase 1/2, c-Jun N-terminal kinase and p38 have been shown to mediate Cox-2 induction in human colon cancer cells (Guo et al., 2001; Liu et al., 2003; Shao et al., 2004; Sun and Sinicrope, 2005) .
On the other hand, nuclear factor of activated T cells (NFAT) is required for optimal induction of Cox-2 promoter activity in a diversity of cell types (Robida et al., 2000; Iniguez et al., 2000; Hernandez et al., 2001; Lara-Pezzi et al., 2002; Duque et al., 2005) . The NFAT family includes four 'classical' members that display a high degree of homology: NFATc2 (also called NFAT1 or NFATp), NFATc1 (2 or c), NFATc3 (4) and NFATc4 (Hogan et al., 2003) . NFAT exists in a highly phosphorylated form in the cytoplasm, which translocates into the nucleus upon dephosphorylation by the phosphatase calcineurin (Cn) in response to increases in intracellular calcium ([Ca 2 þ ] i ), where it binds to enhancer elements of specific genes leading to transcriptional activation. Cn activity can be blocked by cyclosporin A (CsA), thereby preventing the nuclear translocation of NFAT (Hogan et al., 2003) . Although many stimuli have been demonstrated to be able to induce this signaling pathway in non-immune cells (Hogan et al., 2003) , the physiological agents that lead to the activation of NFAT in tumor cells have not been established.
Recent studies have described that bombesin (BBS), a homologue of the mammalian gastrin-release peptide (GRP), induces Cox-2 expression in fibroblasts and epithelial cells, requiring an increase in [Ca 2 þ ] i (Hecht et al., 1997; Guo et al., 2001) . Even more, GRP and its cognate G-protein-coupled receptor (GRP-R), as well as Cox-2, are overexpressed in a substantial fraction of human colorectal carcinomas (38-76% ) (Preston et al., 1995; Carroll et al., 1999 Carroll et al., , 2000 Gupta and Dubois, 2001; Jensen et al., 2001) . BBS/GRP are neurotransmitters expressed mainly in nerve fibers throughout the mammalian gut and in the central nervous system. In addition to their physiological neuroendocrine actions, BBS/GRP have growth-promoting activity in various cancers, including pancreatic, prostate, mammary and small-cell lung carcinomas, which may secrete BBS/ GRP in an autocrine manner (Cuttitta et al., 1985) . Conversely, BBS/GRP antagonists can effectively inhibit tumor growth and slow the progression of premalignant lesions (Iishi et al., 2003; Kanashiro et al., 2003; Yegen, 2003) . The abnormal expression of BBS/ GRP and GRP-R in human colon cancers has been correlated with more invasive characteristics of these tumors. Several reports show that BBS induces morphological and adhesive, rather than proliferative, effects on human colon carcinoma cells, suggesting that expression of BBS/GRP-R may regulate cell differentiation and thus contribute to their malignant properties (Saurin et al., 1999 (Saurin et al., , 2002 Jensen et al., 2001) .
Altogether, these observations prompted us to examine the regulation of Cox-2 expression by BBS in human colon adenocarcinoma cell lines. Our results show that induction of Cox-2 expression by BBS in these cells requires activation of the Ca 2 þ /Cn/NFAT pathway. NFAT is translocated to the nucleus upon BBS stimulation where it binds to NFAT response elements in the promoter region of Cox-2 gene that are essential for Cox-2 transcriptional induction. Moreover, BBS through Cox-2 induction promotes migration of colon carcinoma cells. These findings demonstrate the participation of NFAT in BBS-mediated induction of genes involved in colon carcinoma invasiveness such as Cox-2.
Results
BBS stimulates Cox-2 expression and PGE 2 production BBS induced a dose-dependent increase in the expression of Cox-2 mRNA in serum-starved Caco-2 cells, reaching maximum levels in cells treated with 100 and 1000 nM BBS, although some effect can be seen at 10 nM ( Figure 1a) . Kinetics experiments showed maximal induction of Cox-2 after 4 h incubation in the presence of BBS (Figure 1b) . Analysis of Cox-2 protein levels by Western blot also revealed a time-dependent increase that was clearly observed at 4 h following BBS (100 nM) stimulation, with the highest expression between 8 and 24 h (Figure 1c) . Interestingly, Cox-2 protein induction was markedly inhibited by RC-3940-II, a well-known BBS/GRP-R antagonist (Cai et al., 1994) , indicating the specificity of BBS action (Figure 1c) . Expression of the non-inducible Cox-1 isoform was almost negligible, and was not affected by BBS treatment (not shown).
To assess whether induction of Cox-2 expression was associated with an increase in enzymatic activity, prostaglandin E 2 (PGE 2 ) release by Caco-2 cells was measured. BBS (100 nM) induced a significant timedependent release of PGE 2 to the media compared to untreated cells over a period of 24 h (Po0.001) (Figure 1d ). PGE 2 levels were drastically reduced in the supernatant from cells incubated in the presence of a Cox-2-selective inhibitor (NS398 1 mM) (Po0.02), further confirming the involvement of Cox-2 in the increase of PGE 2 production upon BBS stimulation. Similar induction was observed in other carcinoma cell lines as HT-29 (data not shown).
Involvement of Ca
2 þ /Cn signaling pathway in BBS-mediated upregulation of Cox-2 expression Agonist binding to GRP-R results in the rapid release of Ca 2 þ from inositol 1,4,5-triphosphate-sensitive stores (Hellmich et al., 1999) . To test whether BBS induced an increase in [Ca 2 þ ] i , Caco-2 cells were loaded with the Ca 2 þ indicator dye Fura-2/AM and stimulated with BBS (100 nM) in the presence or absence of the BBS antagonist RC-3940-II. BBS elicited a rapid increase in [Ca 2 þ ] i , which was blocked by pretreating the cells with RC-3940-II (10 nM) (Figure 2a ), confirming the expression of functional BBS/GRP-R on these cells (Carroll et al., 2000) . This augmentation in [Ca 2 þ ] i could mediate activation of Cn, thus leading to NFAT activation and subsequently to Cox-2 induction. As shown in Figure 2b , inhibition of Cn activity by CsA treatment diminished Cox-2 protein expression induced by BBS. Accordingly, CsA-mediated inhibition of Cox-2 expression results in a significant (Po0.05) reduction in BBS-induced PGE 2 production ( Figure 1d ). Taken together, these data suggest that BBS upregulation of Cox-2 expression in Caco-2 cells requires an increase in [Ca 2 þ ] i and a subsequent Cn activation.
BBS induces nuclear translocation of NFAT and its binding to DNA We next investigated whether NFAT, a Ca 2 þ /Cnregulated transcription factor, participates in Cox-2 induction by BBS. Our results showed that NFATc1 is present in the cytoplasm of untreated Caco-2 cells and is rapidly (30 min) dephosphorylated upon BBS stimulation and translocated into the nucleus (Figure 3a) . Pretreatment with CsA (1 mg/ml) inhibited NFAT translocation, thereby resulting in an accumulation of cytoplasmic NFATc1 protein.
To analyse DNA binding of BBS-activated NFAT to the distal NFAT (dNFAT) and proximal NFAT (pNFAT) sequences of the human Cox-2 promoter, we performed electrophoretic mobility shift assays (EMSAs) with nuclear extracts of Caco-2 cells treated with BBS (100 nM) or calcium ionophore A23187 (Ion, 1 mM) as a control, using oligonucleotides from pNFAT or dNFAT sites of Cox-2 promoter (Iniguez et al., 2000) ( Figure 3b ). Both the pNFAT and dNFAT Cox-2 probes specifically bound nuclear proteins from Caco-2 cells. The retarded complexes were efficiently competed with a 20-fold molar excess of the respective cold oligonucleotides. Although some constitutive binding was observed in unstimulated cells, especially to the pNFAT probe, BBS induced an enhanced binding to the same level than Ion. Furthermore, these inducible complexes were severely diminished in nuclear extracts from cells stimulated with BBS in the presence of CsA.
To determine unambiguously the presence of the NFATc1 protein in the bands, we performed EMSAs using an anti-NFATc1 polyclonal antiserum, which clearly prevented the binding of specific complexes allowing the formation of more retarded complexes likely constituted by DNA/NFAT/antibody. As a control, EMSAs were carried out in the presence of preimmune serum (Figure 3b ). These data suggest that the binding of NFATc1 protein to the Cox-2 dNFAT and pNFAT sites in response to BBS treatment of Caco-2 cells.
Transcriptional regulation of the Cox-2 promoter by BBS We next analysed whether the effect of BBS on Cox-2 expression was taking place at the transcriptional level. For this, Caco-2 cells were transfected with a Cox-2 promoter/luciferase construct spanning from nucleotide À1796 to þ 104 bp relative to the human Cox-2 gene transcription start site (P2-1900-Cox-2-LUC) (Iniguez et al., 2000) . As shown in Figure 4 , BBS (100 nM) induced a fourfold increase (Po0.001) in luciferase activity in transiently transfected cells compared to untreated controls. CsA treatment significantly inhibited BBS-mediated induction of Cox-2 promoter. To map the region responsible for BBS inducibility, we used Cox-2 promoter deletion constructs. BBS significantly induced transcription driven by constructs with deletions up to À88 of the Cox-2 promoter region (P2-1900 to P2-192), although a statistically significant decrease in inducibility was observed in P2-192 construct that contains the pNFAT site ( Figure 5a ). However, deletion of cis-acting elements mapping between the nucleotides at positions À88 and À46 in the promoter region completely abolished the BBSmediated increase of luciferase activity.
Given the relevance of the region spanning from nucleotides À170 to À46 for the induction of the Cox-2 promoter by BBS, we next determined the contribution of the two NFAT sites present in this region to the overall transcriptional regulation of the Cox-2 promoter by BBS by using the P2-274 containing specific mutations within the dNFAT site, the pNFAT site or both (Iniguez et al., 2000) . Transfection experiments showed that mutation of the dNFAT (P2-274 dNFAT mut) or pNFAT (P2-274 pNFAT mut) sites resulted in a 29 and a 49% loss in the BBS-induced Cox-2 promoter activity, respectively, whereas double mutation of both NFAT (P2-274 p-and dNFAT mut) sites drastically reduced the activation of the promoter by BBS. Mutagenesis of the AP-1-like site (P2-274 AP-1 mut) also affected the inducibility of the Cox-2 promoter by BBS, reflecting a possible contribution of AP-1 to BBSmediated Cox-2 induction ( Figure 5b ).
To further confirm the involvement of NFAT activation in the transcriptional regulation mediated by BBS in Caco-2 cells, we co-transfected expression Activation of NFATc1 in Caco-2 colon carcinoma cells. Caco-2 cells were incubated for 30 min with BBS (100 nM). CsA (1 mg/ml) was added 30 min before stimulation. Fractionated extracts from both untreated and treated cells were analysed by Western blotting with an antiserum to NFATc1. Arrows indicate the phosphorylated cytosolic or dephosphorylated nuclear forms of NFATc1. Cyto, cytosolic extracts; Nucl, nuclear extracts. (b) EMSA analysis of NFATc1 binding to the pNFAT and dNFAT sites of the human Cox-2 gene (Cox-2 pNFAT and dNFAT, respectively). Caco-2 cells were incubated with medium, BBS in the presence or absence of CsA or with calcium Ion (0.5 mM) for 30 min as indicated. Nuclear extracts were analysed by EMSA using Cox-2 pNFAT (upper panel) or Cox-2 dNFAT (lower panel) radiolabeled probes. A 50-fold molar excess of unlabeled Cox-2 pNFAT and dNFAT oligonucleotides (BBS þ Cox-2 pNFAT and BBS þ Cox-2 dNFAT, respectively) was added to determine specific binding. The NFATc1 antiserum (NFATc1 Ab) or preimmune serum was added to the extracts before incubation with the probes. Closed arrows indicate specific complexes. White arrows indicate supershifted complexes. vectors, encoding either a functional NFATc2 protein (hemagglutinin (HA)-NFAT) or a dominant-negative version of NFATc1 (dnNFAT), together with the P2-274-Cox-2-LUC or the NFAT-LUC reporter plasmids. BBS treatment was able to activate both reporters and to augment the induction mediated by overexpression of HA-NFAT. More interestingly, expression of dnNFAT, previously described to abolish NFAT-dependent promoter activity (Iniguez et al., 2000) , abrogated BBSinduced transcription of both reporters (Figure 6a and b) , further supporting the hypothesis of the involvement of NFAT signaling in the regulation of Cox-2 gene expression by BBS. A similar pattern was observed using phorbol 12-myristate 13-acetate (PMA) þ Ion as stimuli for both NFAT-LUC and P2-274-Cox-2-LUC reporters (Figure 6c and d) .
BBS stimulates Caco-2 cells invasiveness
Previous results have described the ability of BBS to alter the morphology of colon carcinoma cells increasing tumor invasiveness (Saurin et al., 1999 (Saurin et al., , 2002 . Thus, we investigated whether this kind of modifications effectively occurred in BBS-treated Caco-2 cells, largely reputed as poorly aggressive (Engle et al., 1998) . For this, we used a Matrigel Chamber invasion assay. Under our experimental conditions, this cell type was not able to pass through the Matrigel þ membrane barrier when fetal calf serum (FCS)-free Dulbecco's modified Eagle's medium (DMEM) was introduced into the lower compartment. There was a small number of invading cells when FCS-supplemented medium was used in place of serum-free DMEM (Figure 7a ). As reported previously (Kermorgant et al., 2001) , when 100 ng/ml of hepatocyte growth factor (HGF) were added to the FCS-DMEM, there was a substantial increase in the number of invading cells. BBS addition to either FCSfree or FCS-supplemented medium slightly induced (around twofold) the migration of Caco-2 cells. Interestingly, when Caco cells were pretreated for 3 days in the presence of 100 nM BBS and then subjected to in vitro invasion assay, a significant (Po0.05) increase in cell invasiveness could be observed, independently from the chemoattractants (e.g. FCS-supplemented DMEM with or without BBS or HGF) dispensed into the lower chamber (Figure 7b) . The MDA-MB-231 human breast carcinoma cell line, showing marked invasion capacity in Transwell assays (Munoz-Najar et al., 2006) was used as a positive control. More interestingly, the enhancing effect of BBS treatment was completely abolished by addition of the BBS receptor antagonist RC-3940-II (10 nM) during pretreatment of Caco-2 cells (Po0.01). Similarly, inhibition of Cox-2 by 10 mM NS-398 significantly (Po0.05) decreased BBS-induced cell invasion by 67% on average (Figure 7c) . BBS was also able to induce migration in Transwell assays of another human carcinoma cell line as HT29 to the same extent to that promoted by pre-incubation of those cells with PGE 2 (Figure 7d ).
Discussion
Aberrant expression of Cox-2, BBS/GRP and GRP-R has been observed in a variety of tumors, including colorectal carcinomas (Preston et al., 1995; Carroll et al., 1999 Carroll et al., , 2000 Gupta and Dubois, 2001; Jensen et al., 2001) and several lines of evidence suggest a link among these proteins in cancer progression (Hecht et al., 1997; Guo et al., 2001; Iishi et al., 2003) . We have analysed the potential association between BBS-mediated signaling and Cox-2 in colon carcinoma cells, demonstrating that BBS stimulation of Caco-2 cells leads to a rapid upregulation of Cox-2 expression at both mRNA and protein levels resulting in increased production of PGE 2 . This effect can be attributed to BBS binding to a functional GRP-R that mediates mobilization of intracellular Ca 2 þ , likely through a Ga q protein, as it was blocked by the specific antagonist RC-3940-II. This effect was clearly observed at 100 nM BBS, which is higher than the reported IC 50 for the binding to the receptor (around 1 nM) (Ryan et al., 1999) . However, the affinity of labeled peptides for the receptor does not always correlate with the concentrations required to observe a functional effect. Moreover, peptidases present in the serum may interfere with BBS/GRP and GRP-R binding or function (Jensen et al., 2001) , which may explain the discrepancies between data of binding affinities (measured in the absence of serum and after short periods of incubation) and concentrations reported for biological effects (requiring a longer period of incubation in the presence of serum). In this regard, similar concentrations of GRP/BBS as those used in our study have been reported for the induction of Cox-2 in other cell types (Hecht et al., 1997; Guo et al., 2001) as well as for regulating motility of Caco-2 cells upon BBS treatment (Glover et al., 2005) . Results from triplicate assays of three independent experiments are shown as mean fold induction 7s.e. Deletions ranging from À1796 to À46 relative to the transcription start site of the Cox-2 promoter were used. Consensus sequences are denoted by boxes. The asterisks indicate statistically significant differences (*Po0.05; **Po0.001) between BBS and control samples; ( J Po0.05 respect to the longest construct P2-1900). (b) Role of NFAT in Cox-2 promoter induction by BBS. Caco-2 cells were transiently transfected with the P2-274-Cox-2 promoter construct, and the same construct containing dNFAT and/or pNFAT sites, and/or AP-1 site mutated (indicated by X). Three hours after transfection, the cells were stimulated with BBS (100 nM) for 16 h and luciferase activity was determined. The activity is expressed as percentage of induction relative to that achieved in cells transfected with the P2-274-Cox-2 promoter construct. One out of three separate experiments performed is shown.
Two NFAT binding sites in the Cox-2 promoter are essential for BBS-induced expression of Cox-2, one of them resembling an NFAT/AP-1 composite site. Mutation of either the NFAT or the AP-1 component of this site strongly diminished BBS-induced Cox-2 transcription in agreement with the well-known cooperation between NFAT and AP-1 necessary to drive efficiently transcription of a variety of NFAT-dependent genes (Hogan et al., 2003) . In RIE/GPRP-R cells, BBSmediated transcriptional induction of the Cox-2 gene is also calcium dependent, requiring activation of components of the AP-1 transcription factor complex, such as Fos/Jun proteins (Guo et al., 2001) . Moreover, involvement of Gaq-coupled receptors as the GRP-R in the activation of NFAT and in the induction of NFATdependent genes has been described in a variety of cell types (Boss et al., 1996; Horsley and Pavlath, 2002; Liu et al., 2004) . Noticeably, recent reports have proposed that NFAT proteins may play an important role in cancer, having shown a direct involvement of NFATmediated transcriptional regulation of different genes, including Cox-2 (Jauliac et al., 2002; Lara-Pezzi et al., 2002; Saurin et al., 2002; Neal and Clipstone, 2003; Holzmann et al., 2004; Yiu and Toker, 2006) .
As mentioned above, GRP-R and Cox-2 expression in human colon cancer cells correlates with more invasive characteristics. Our findings show that in spite of the poor aggressiveness displayed by Caco-2 cells, their capacity to migrate towards Matrigel was greatly facilitated when they were pre-incubated with BBS. This enhanced invasion was induced through GRP-R, as the number of invading cells under BBS drastically decreased by treatment with the specific antagonist RC-3940-II. Furthermore, the Cox-2 selective inhibitor NS-398 was also able to reduce strongly BBS-promoted cell invasion, suggesting that this enzyme is involved in Caco-2 cells invasiveness. A similar effect of BBS on migration was observed with HT-29 colon carcinoma cells. BBS treatment may enhance cell invasion/migration by different mechanisms, some of which could be mediated through its ability to induce NFAT-dependent transcriptional activation of Cox-2. Previous reports have shown that BBS acts as an invasion-promoting agent in prostate and colon cancer cell lines, although the precise molecular mechanism(s) by which BBS causes these effects are unknown. BBS was shown to stimulate tyrosine phosphorylation of several focal adhesion proteins which mediate colon cancer cell motility (Aprikian et al., 1997; Rozengurt et al., 2002; Glover et al., 2005) . BBS also enhances invasion of Isreco1 colon carcinoma cells through unidentified effector proteins downstream the Rho signaling pathway (Saurin et al., 2002) . Moreover, BBS has been proved to induce the expression and activation of the extracellular matrix proteinases urokinase-type plasminogen activator and metalloproteinase-9, as well as the proangiogenic factors interleukin-8 and vascular endothelial growth factor, linked to increased metastatic potential in prostate cancer cells (Festuccia et al., 1998 (Festuccia et al., , 2002 Levine et al., 2003) . In addition, our results show the involvement of NFAT-mediated induction of genes implicated in tumor progression such as Cox-2 in the pro-tumoral effects of BBS. NFAT has been involved in promoting breast and colon carcinoma motility and invasion through Matrigel, mediating integrin-dependent events (Jauliac et al., 2002; Chen and O'Connor, 2005) . In a recent report, Yiu and Toker (2006) have shown in breast cancer cells that increased expression and activity of NFAT-induced Cox-2 expression and PGE 2 production, resulting in increased invasion that was reduced by inhibiting Cox-2 expression or activity (Yiu and Toker, 2006) . Multiple evidences support the involvement of Cox-2-derived PGs in tumor progression by their ability to enhance migration and invasion of carcinoma cells. Cox-2 expression in colon or breast cancer cell lines increases the expression of enzymes capable of digesting the basal membrane presumably contributing to the observed increased ability to invade through a layer of Matrigel (Tsujii et al., 1997) . These effects are related to PG-mediated upregulation of metalloproteinases, b-catenin and diverse growth factors receptors (Tsujii et al., 1997; Pai et al., 2003; Singh et al., 2005) . Nevertheless, it remains to be elucidated what is the contribution of NFAT/Cox-2 to the previously described events occurring upon BBS treatment in carcinoma cells. In agreement to our data showing inhibition of BBS-mediated enhanced invasion of Caco-2 cells by NS398, Iishi et al. (2003) reported that Nimesulide, a Cox-2 inhibitor, was able to suppress BBS-enhanced MMP-9 activity and peritoneal metastasis of intestinal adenocarcinomas in rats. Based on our findings, we postulate that BBSmediated cell growth, invasiveness and tumor progression in human colon cancer depend on the activation of the Ca 2 þ /Cn/NFAT signaling pathway that leads to an upregulation of genes involved in the tumoral phenotype such as Cox-2. Identifying changes in the gene expression pattern upon BBS treatment of colon carcinoma cells may further contribute to our understanding of the pathogenesis of colorectal carcinoma.
Materials and methods
Reagents BBS, PMA and A23187 calcium Ion were purchased from Sigma. The Random Primers DNA Labelling System kit, Optiminimum essential medium (MEM) and Lipofectamine were obtained from Invitrogen (Carlsbad, CA, USA). enhanced chemiluminescence system was purchased from Amersham Pharmacia (Buckinghamshire, England). BCA Protein Assay reagent and Restore Western Blot Stripping buffer were obtained from Pierce (Rockford, IL, USA). The Luciferase Assay System and lysis buffer were purchased from Promega (Madison, WI, USA). Anti-Cox-2 antibody and the Cox-2 inhibitor NS398 were obtained from Alexis (San Diego, CA, USA). Anti-human b-actin and horseradish peroxidaseconjugated antibodies were purchased from Santa Cruz (Santa Cruz, CA, USA), whereas anti-NFATc1 antibody was described previously (Iniguez et al., 2000) . PGE 2 and the enzyme-linked immunosorbent assay (ELISA) kit for the determination of PGE 2 were obtained from Cayman. Fura-2/AM was purchased from Molecular Probes (Carlsbad, CA, USA). Trizol was obtained from Invitrogen. Nylon membranes were purchased from Schleicher and Schuell (Brentford, UK). CsA was obtained from Sandoz (Holzkirchen, Germany). Specific BBS antagonist (RC-3940-II) was kindly provided by Andrew Schally (Tulane University, New Orleans).
Cell culture
The Caco-2 human intestinal cell line was obtained from the American Type Culture Collection. Cells were cultured using MEM supplemented with 20% FCS for Caco-2 or 10% FCS for HT29, 100 U/ml penicillin, 100 mg/ml streptomycin, 1 mM ) were serum-starved for 72 h and seeded in the upper compartment, whereas in the lower chamber there was DMEM supplemented with chemoattractants: 20% FCS with or without 100 ng/ml HGF and 100 nM BBS where indicated. (b) Caco-2 cells were serum-starved as above but in the presence or absence of 100 nM BBS as indicated. In the lower chamber, there was DMEM supplemented with 20% FCS plus, 100 ng/ml HGF or 100 nM BBS, where indicated. The MDA-MB-231 cell line was used as positive control in the invasion assay. (c) Caco-2 cells were serum-starved as above in the presence or absence of 100 nM BBS, with or without the addition of 10 nM RC-3940-II or 10 mM NS-398. In the lower chamber, there was DMEM supplemented with 20% FCS and 100 nM BBS, where indicated. (d) HT-29 cell were serum-starved and pre-incubated with 100 nM BBS or 1 mM PGE 2 . In the lower chamber, there was DMEM supplemented with 20% FCS. After 3 days of culture, cells that passed across the membrane were fixed, stained and counted. Data represent the number (mean7s.e. of four independent experiments, each performed in duplicate) of invading or migrating cells. Area corresponds to the surface occupied by the ocular grid at Â 400 magnification. sodium pyruvate, 2 mM L-glutamine and 1% non-essential amino acids at 371C in a 5% CO 2 atmosphere. Cells were used between passages 15 and 45.
Intracellular calcium measurements
Agonist-induced changes in [Ca 2 þ ] i were detected using the Ca 2 þ -sensitive dye Fura-2/AM as described by Hellmich et al. (1999) . Briefly, cell monolayers at 80% confluence were trypsinized, washed and then loaded with 1 mM Fura-2/AM under continuous stirring for 30 min at 371C. The cells (2 Â 10 6 /ml) were treated with 100 nM BBS or 10 nM RC-3940-II, and placed in an Aminco Bowman Series 2 spectrofluorometer (Thermo). The fluorescence signal of Fura-2 was recorded, with excitation and emission at 340 and 510 nm, respectively.
RNA isolation and Northern blot analysis
Total RNA was extracted from Caco-2 cells by using Trizol reagent according to the manufacturer's instructions. RNA samples (20 mg/lane) were separated on formaldehyde-agarose gels and blotted onto nylon membranes. The blots were hybridized with Cox-2 DNA probe labeled with [a-32 P]dCTP by random primer extension. After overnight hybridization at 651C and thorough washing, the blots were exposed to X-ray film for autoradiography as described (Hernandez et al., 2001) . To ensure RNA integrity and to confirm equal loading among lanes, the filters were stripped and rehybridized with a probe for glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Densitometric analysis was performed using NIH Image 1.62 software to quantify the results.
PGE 2 measurements
Cells were maintained for 12 h in culture medium supplemented with 0.5% FCS, then pretreated or not with 200 ng/ml CsA or 1 mM NS398 for 2 h, and further stimulated with 100 nM BBS for the indicated times. Media supernatants were collected and analysed for PGE 2 by ELISA (Hernandez et al., 2001 ).
Immunoblot analysis
Immunoblotting was carried out as described elsewhere (Iniguez et al., 2000) . Cells were disrupted and solubilized extracts (20 mg) were separated in 6% (only for analysis of NFAT translocation to the nucleus) or 10% sodium dodecyl sulfate-polyacrylamide gels, and transferred to nitrocellulose filters. After blocking for 2 h with 5% non-fat dried milk in Tris-buffered saline containing 0.1% Tween-20, the membranes were probed 2 h at 371C with murine monoclonal antibody against Cox-2 (diluted 1:1000 in blocking buffer), polyclonal goat anti-human b actin antibody (1:1000), or polyclonal goat anti-human NFATc1 antibody (1:2000). The filters were washed and incubated with the corresponding secondary antibody linked to horseradish peroxidase at 1:10,000 dilution, and the stained bands were visualized by a chemiluminescent peroxide substrate.
Plasmid constructs
Human Cox-2 promoter constructs spanning from À1796 (P2-1900-LUC), À521 (P2-625-LUC), À327 (P2-431-LUC), À170 (P2-274-LUC), À88 (P2-192-LUC) and À46 (P2-150-LUC) to þ 104 bp relative to the transcription start site of the human Cox-2 gene and the P2-274-LUC plasmid with binding sites for NFAT, or AP-1, or both mutated were described (Iniguez et al., 2000) . The reporter construct NFAT-LUC contains three tandem copies of the NFAT binding site fused to the IL-2 minimal promoter. The EF-BOS-NFAT1 plasmid contains the cDNA encoding murine NFATc2, modified to encode an influenza HA peptide at the N-terminus of the expressed protein (Luo et al., 1996) . The pSH102CD418 expression vector (a kind gift from Gerald Crabtree, Stanford University, Stanford, CT, USA) derives from pBJ5 and encodes an NFATc1 deletion mutant (1-418) that functions as a dominant negative for all NFAT isoforms (Northrop et al., 1994) .
Transfection and luciferase assays Caco-2 cells were transfected by Lipofectamine as described (Iniguez et al., 2000) . Briefly, exponential growing cells (1.25 Â 10 5 /well) cultured in 24-well plates were incubated for 3 h at 371C with a mixture of 0.5-1 mg of the corresponding reporter plasmid and Lipofectamine-containing Opti-MEM. In co-transfection experiments, 0.15-1.5 mg of the corresponding expression plasmid was included. The total amount of DNA in each transfection was kept constant by using the empty expression vectors. Complete medium was then added to cells and incubated at 371C for additional 16 h. Transfected cells were exposed to different stimuli as indicated. Then, cells were harvested and lysed. Luciferase activity was determined by using a luciferase assay system with a luminometer Monolight 2010 (Analytical Luminescence Laboratory). Transfection experiments were performed in triplicate. Data of luciferase activity are presented as fold induction (observed experimental relative luciferase units (RLU)/basal RLU in absence of any stimulus). Results were normalized for extract protein concentrations measured with a Bradford assay kit.
Electrophoretic mobility shift assay Nuclear extracts were prepared from Caco-2 cells as described (Martinez-Martinez et al., 1997) with minor modifications. In brief, 5 mg of nuclear protein was incubated with 1 mg of poly(dI-dC) DNA carrier in DNA binding buffer (10% (wt/ vol) polyvinylethanol, 12.5% (vol/vol) glycerol, 50 mM Tris, pH 8, 2.5 mM dithiothreitol, 2.5 mM ethylenediaminetetraacetic acid) for 30 min at 41C. Then, 10 5 counts per minute (c.p.m.) (10 8 c.p.m./mg) of the 32 P-labeled double-stranded oligonucleotide (2 mg) were added, and the reaction was incubated at room temperature for 30 min. For competition experiments, a 50-fold molar excess of unlabeled oligonucleotide was added before the addition of the probe. Supershift assays were performed by incubating nuclear extracts with either preimmune serum or anti-NFATc1 antibody for 15 min at 41C before the addition of the probe. DNA-protein complexes were resolved by electrophoresis in 4% nondenaturing polyacrylamide gels and were subjected to autoradiography.
The following synthetic oligonucleotides (5 0 -3 0 ) were used as probes/competitors in EMSAs (factor binding sites are underlined): tcgaCAAGGGGAGAGGAGGGAAAAATTTGTG GC (nucleotides À117 to À91 containing the putative dNFAT site of the human Cox-2 promoter); and tcgaCAAAAGGCG GAAAGAAACAGTCATTTC (nucleotides À82 to À58 containing the putative AP-1-pNFAT site of the human Cox-2 promoter).
In vitro cell migration and invasion assays Invasion and migration assays were carried out in Transwell filter chambers coated or not with Matrigel (Corning-Costar, Cambridge, MA, USA) (Albini et al., 1987) . Caco-2 cells were preincubated in FCS-free DMEM with 0.1% bovine serum albumin, in the presence or absence of 100 nM BBS, with or without the addition of BBS-R antagonist RC-3940-II (10 nM) or Cox-2 inhibitor NS-398 (10 mM), and then seeded (1 Â 10 5 ) in the upper chamber equipped with a 12 mm Matrigel-coated polycarbonate membrane. The culture medium was changed daily along 3 days. DMEM supplemented with 20% FCS was introduced into the lower compartment with or without recombinant human HGF (R&D Systems, Minneapolis, MN, USA) at 100 ng/ml, and with or without 100 nM BBS. To analyse the mechanisms associated with cell invasiveness, we used chemoattractants diluted in FCS-supplemented medium, as described by Kermorgant et al. (2001) . In the lower chamber there was DMEM supplemented with 20% FCS. After 72 h of culture, the non-migratory cells on the upper surface of the filter were mechanically removed by scraping and the membranes fixed and stained with Diff-Quick (Baxter Scientific Products, McGraw Park, IL, USA). Cell migration was microscopically quantified by counting cells on the bottom surface of the filter at Â 400 magnification, using a calibrated ocular grid, in 16 representative areas per well. Experiments were carried out in duplicate and several independent sets of experiments for each type of migration assay were performed.
In the case of HT-29 only migration assays were carried out as above, but in absence of matrigel in a 8 mm pore size Polycarbonate Membrane Transwell Inserts (Corning-Costar, Cambridge, MA, USA). HT-29 cells were serum-starved and pre-incubated with 100 nM BBS or 1 mM PGE 2 . Cell migration was microscopically quantified by counting cells on the bottom surface of the filter, analysing captured images at Â 10 magnification with the ImageJ v1.36b Software (Wayne Rasband, NIH, Bethesda, MD, USA).
Statistical analysis
Statistical analysis was performed by using GraphPad InStat 3.05 software. Comparisons between groups were made by using the one-way analysis of variance test. A difference between groups of Po0.05 was considered significant.
